Robitussin and Trilipix drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among 4 people who take Robitussin and Trilipix. Common interactions include renal failure among females, and alanine aminotransferase increased among males.
The phase IV clinical study analyzes what interactions people who take Robitussin and Trilipix have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
4 people who take Robitussin and Trilipix together, and have interactions are studied.
What is Robitussin?
Robitussin has active ingredients of guaifenesin. Currently, eHealthMe is studying from 3,325 Robitussin users.
What is Trilipix?
Trilipix has active ingredients of choline fenofibrate. It is used in high blood cholesterol. Currently, eHealthMe is studying from 5,881 Trilipix users.
Number of Robitussin and Trilipix reports submitted per year:
Common Robitussin and Trilipix drug interactions by gender *:
female:
- Renal failure
- Hyperparathyroidism secondary
- Nephrogenic anaemia
- Tubulointerstitial nephritis
- Chronic kidney disease
male:
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Bradycardia
- Cough
- Dyspepsia
- Nasopharyngitis
- Nausea
- Respiratory failure
- Septic shock
Common Robitussin and Trilipix drug interactions by age *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Chronic kidney disease
- Renal failure
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Bradycardia
- Hyperparathyroidism secondary
- Nephrogenic anaemia
- Respiratory failure
- Septic shock
- Tubulointerstitial nephritis
* Approximation only. Some reports may have incomplete information.
Do you take Robitussin and Trilipix?
Personalize this study to your gender and ageHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
Drug side effects by duration, gender and age:
- Robitussin side effects (3,325 reports)
- Trilipix side effects (5,881 reports)
Common Robitussin drug interactions:
- Robitussin and Tylenol: 547 reports
- Robitussin and Aspirin: 531 reports
- Robitussin and Albuterol: 409 reports
- Robitussin and Vitamin d: 393 reports
- Robitussin and Prednisone: 362 reports
- Robitussin and Zofran: 334 reports
- Robitussin and Gabapentin: 297 reports
- Robitussin and Lisinopril: 290 reports
- Robitussin and Omeprazole: 261 reports
- Robitussin and Vitamin d3: 258 reports
Browse interactions between Robitussin and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zCommon Trilipix drug interactions:
- Trilipix and Aspirin: 1,142 reports
- Trilipix and Crestor: 799 reports
- Trilipix and Niaspan: 708 reports
- Trilipix and Metformin: 699 reports
- Trilipix and Lisinopril: 691 reports
- Trilipix and Lipitor: 552 reports
- Trilipix and Simvastatin: 492 reports
- Trilipix and Nexium: 472 reports
- Trilipix and Plavix: 440 reports
- Trilipix and Fish oil: 415 reports
Browse interactions between Trilipix and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on guaifenesin and choline fenofibrate (the active ingredients of Robitussin and Trilipix, respectively), and Robitussin and Trilipix (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Robitussin and Trilipix.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Depakote and Aspirin drug interaction - now
- Prohance and Hypersensitivity - 27 seconds ago
- Omeprazole and Coronary Arterial Stent Insertion - 30 seconds ago
- Oxycontin and Muscle Strain - 33 seconds ago
- Eliquis and Joint Stiffness - a minute ago
- Naproxen and Trandolapril And Verapamil Hydrochloride drug interaction - a minute ago
- Omnaris and Head Injury - a minute ago
- Propofol and Colcrys drug interaction - a minute ago
- Maxipime and Folic Acid drug interaction - a minute ago
- Dexedrine and Pegasys drug interaction - 2 minutes ago